References
- Merchav S, Wagemaker G, Souza LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 1991; 5: 340–346.
- Raza A, Gezer S, Mundle S et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276.
- Acosta JC, Richard C, Delgado MD et al. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther 2003; 2: 893–900.
- Capizzi, R. L. Amifostine: the preclinical basis for broad-spectrumselective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer 1996; 23: 2–17.
- Balzarotti M, Grisanti S, Granzow K et al. Ex vivo manipulationof hematopoietic stem cells for transplantation: the potential role of amifostine. Semin Oncol 1999; 26: 66–71.
- Preisler HD, Li B, Yang BL et al. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin. Clin Cancer Res 2000; 6: 807–812.
- Douay L. Negative selection and protection of normal progenitorcells for autografting. Bone Marrow Transplant 1998; 22: 423–430.
- Raza A, Qawi H, Lisak L et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000; 95: 1580–1587.
- List AF, Brasfield F, Heaton R et al. Stimulation of hematopoiesisby amifostine in patients with myelodysplastic syndromes. Blood 1997; 90: 3364–3369.
- Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997; 99: 625–631.
- Glover D, Glick JH, Weiler C, Hurowitz S, Kligermann MM. WR-2721 protects against the hematologic toxicity of cyclopho-sphamide: a controlled phase 11 trial. J Clin Oncol 1986; 4: 574–578.
- List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 1998; 12: 1596–1602.
- Grossi A, Fabbri A, Santini V et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 2000; 85: 367–371.
- Hofmann WK, Seipelt G, Ottmann OG et al. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann Hematol 2000; 79: 255–258.
- Tefferi A, Elliott MA, Steensma DP et al. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res 2001; 25: 183–185.
- Neumeister P, Jaeger G, Eibl M, Sormann S, Zinke W, Linkesch W. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodys-plastic syndrome. Leuk Lymphoma 2001; 40: 345–349.
- Galanopoulos A, Kritikou-Griva E, Gligori J et al. Treatment of patients with myelodysplastic syndrome with amifostine. Leuk Res 2001; 25: 665–671.